|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
GYN: New Blood Test for Ovarian Cancer?From: art fougner, md (evsono@pipeline.com)Thu Feb 14 06:33:06 2008
The phase II clinical trial led by Mor included 500 patients -- 350 healthy controls and 150 ovarian cancer patients. Mor and colleagues validated the previous research -- which showed 95 percent effectiveness -- and used a new platform called multiplex technology to simplify the test into one single reaction using very small amounts of serum from the blood. The new platform uses six protein biomarkers instead of four, increasing the specificity of the test from 95 percent to 99.4 percent, Mor said. "This is the most sensitive and specific test currently available," Mor said in a statement. "Previous tests recognized 15 percent to 20 percent of new tumors http://www.upi.com/NewsTrack/Health/2008/02/13/blood_test_detects_ovarian_cancer_early/8345/ Fingers crossed ... Art
-- art fougner, md "May The Wings of Liberty Never Lose a Feather." - Jack Burton
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Tue Sep 2 05:12:35 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.